Expressions on Evaporation: Clinical Perspectives on the Management of Dry Eye Disease (CME Monograph)
Dry eye disease is among the most common diseases affecting the eye, and its primary cause is meibomian gland dysfunction (MGD). MGD can be easily diagnosed by clinical evaluation of the quality of meibum expressed from meibomian glands. Although treatments are available to help manage the symptoms and signs of MGD, new and emerging therapies offer the opportunity to address several aspects of the underlying pathophysiology of MGD. In this educational activity, an expert panel will discuss the pathophysiology of MGD and MGD-associated dry eye disease, review current treatment options, and forecast the role of new and emerging therapies in the management of these conditions.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Review the function of the tear film in maintaining a healthy ocular surface
- Use diagnostic strategies that examine meibomian gland function in routine practice
- Discuss limitations of currently available treatment options for meibomian gland dysfunction–associated dry eye disease
- Evaluate clinical trial data for agents under development for the treatment of meibomian gland dysfunction–associated dry eye disease
Banner image: Illustration of the tear film (close up). The lipid layer is the outermost layer of the tear film and is produced by meibomian glands (yellow lid structures). A healthy lipid layer prevents excessive evaporative loss from the ocular surface.
|Laura M. Periman, MD (Chair)
Founder and Director of Dry Eye Services and Clinical Research
Periman Eye Institute
|Marguerite B. McDonald, MD, FACS
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Clinical Professor of Ophthalmology
Tulane University Health Sciences Center
New Orleans, Louisiana
Ophthalmic Consultants of Long Island
Oceanside, New York
|Lisa M. Nijm, MD, JD
Assistant Professor of Ophthalmology
University of Illinois Eye and Ear Infirmary
Founder and Medical Director
Warrenville EyeCare and LASIK Center
|William Trattler, MD
Director of Cornea
Center for Excellence in Eye Care
Vice Chair of Research
Department of Ophthalmology
Herbert Wertheim College of Medicine
Florida International University
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Marguerite B. McDonald, MD, is a consultant for Akorn Operating Company LLC, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCULUS Inc, OCuSOFT Inc, Orca Surgical, Oyster Point Pharma, Inc, Santen Inc, Strōma Medical Corporation, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in Ocuphire Pharma.
Lisa M. Nijm, MD, JD, is a consultant for AbbVie Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Visus Therapeutics, and Zeiss; is an advisory board member of Azura Ophthalmics and Trukera Medical; is on the speaker bureau for Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in Trukera Medical.
Laura M. Periman, MD, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Aldeyra Therapeutics, Allergan, Azura Ophthalmics, Bausch & Lomb Incorporated, Eyevance, Horizon Therapeutics plc, Kala Pharmaceuticals, Lumenis, Myze LLC, Novartis Pharmaceuticals Corporation, NuSight Medical, Olympic Ophthalmics Inc, Quidel Corporation, Santen Inc, ScienceBased Health, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, ThermaMEDx, and Visant Medical, Inc; is on the speaker bureau for AbbVie Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Eyevance, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, NuSight Medical, Olympic Ophthalmics Inc, Quidel Corporation, Santen Inc, ScienceBased Health, Scope, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc.
William Trattler, MD, is a consultant for Avellino, Alcon, Azura Ophthalmics, Bausch & Lomb Incorporated, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, Lensar, LLC, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss; is on the speaker bureau for Oculus, Inc, Sight Sciences, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in CXL Ophthalmics.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Tony Realini, MD, is a consultant for iStar Med*, Ivantis Inc*, New World Medical, Ocular Therapeutix, Oyster Point, and Sight Sciences.
* The financial relationship existed during the past 24 months but has now ended.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Bausch & Lomb Incorporated, or Review of Ophthalmology.
©2023 MedEdicus LLC. 290
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation